Modern treatment of Hodgkin lymphomaBARTLETT, Nancy L.Current opinion in hematology. 2008, Vol 15, Num 4, pp 408-414, issn 1065-6251, 7 p.Article

Therapy of relapsed hodgkin lymphomaCASHEN, Amanda F; BARTLETT, Nancy L.Blood reviews. 2007, Vol 21, Num 5, pp 233-243, issn 0268-960X, 11 p.Article

Interdigitating dendritic reticulum cell tumor of lymph nodes: Case report with differential diagnostic considerationsYLAGAN, Lourdes R; BARTLETT, Nancy L; KRAUS, Madeleine et al.Diagnostic cytopathology. 2003, Vol 28, Num 5, pp 278-281, issn 8755-1039, 4 p.Article

Antibodies for the treatment of diffuse large cell lymphomaBLUM, Kristie A; BARTLETT, Nancy L.Seminars in oncology. 2003, Vol 30, Num 4, pp 448-456, issn 0093-7754, 9 p.Article

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaFORERO-TORRES, Andres; LEONARD, John P; GOPAL, Ajay K et al.British journal of haematology. 2009, Vol 146, Num 2, pp 171-179, issn 0007-1048, 9 p.Article

Phase II study of 9-aminocamptothecin in previously treated lymphomas : results of Cancer and Leukemia Group B 9551BARTLETT, Nancy L; JOHNSON, Jeffrey L; WAGNER-JOHNSTON, Nina et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 5, pp 793-798, issn 0344-5704, 6 p.Article

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialWISEMAN, Gregory A; GORDON, Leo I; GRILLO-LOPEZ, Antonio J et al.Blood. 2002, Vol 99, Num 12, pp 4336-4342, issn 0006-4971Article

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of zevalinradioimmunotherapy for low-grade, follicular, or transformed B-cell non-hodgkin's lymphomaWISEMAN, Gregory A; WHITE, Christine A; BELANGER, Richard et al.Critical reviews in oncology/hematology. 2001, Vol 39, Num 1-2, pp 181-194, issn 1040-8428Conference Paper

Gene Expression―Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin LymphomaSCOTT, David W; CHAN, Fong Chun; WOOLCOCK, Bruce W et al.Journal of clinical oncology. 2013, Vol 31, Num 6, pp 692-700, issn 0732-183X, 9 p.Article

Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)GORDON, Leo I; FANGXIN HONG; ADVANI, Ranjana et al.Journal of clinical oncology. 2013, Vol 31, Num 6, pp 684-691, issn 0732-183X, 8 p.Article

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496EVENS, Andrew M; FANGXIN HONG; STIFF, Patrick J et al.British journal of haematology. 2013, Vol 161, Num 1, pp 76-86, issn 0007-1048, 11 p.Article

Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter AnalysisEVENS, Andrew M; ADVANI, Ranjana; KROLL-DESROSIERS, Aimee et al.Journal of clinical oncology. 2013, Vol 31, Num 32, pp 4132-4139, issn 0732-183X, 8 p.Conference Paper

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas : a phase II trial of the Cancer and Leukemia Group BSMITH, Sonali M; GRINBLATT, David; JOHNSON, Jeffrey L et al.British journal of haematology. 2008, Vol 140, Num 3, pp 313-319, issn 0007-1048, 7 p.Article

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic MalignanciesFANALE, Michelle A; FORERO-TORRES, Andres; ROSENBLATT, Joseph D et al.Clinical cancer research (Print). 2012, Vol 18, Num 1, pp 248-255, issn 1078-0432, 8 p.Article

A Phase II Study of the Survivin Suppressant YM155 in Patients With Refractory Diffuse Large B-Cell LymphomaCHESON, Bruce D; BARTLETT, Nancy L; VOSE, Julie M et al.Cancer. 2012, Vol 118, Num 12, pp 3128-3134, issn 0008-543X, 7 p.Article

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaYOUNES, Anas; GOPAL, Ajay K; FORERO-TORRES, Andres et al.Journal of clinical oncology. 2012, Vol 30, Num 18, pp 2183-2189, issn 0732-183X, 7 p.Article

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialTAN, King L; SCOTT, David W; STEIDL, Christian et al.Blood. 2012, Vol 120, Num 16, pp 3280-3287, issn 0006-4971, 8 p.Article

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PETSTRAUS, David J; JOHNSON, Jeffrey L; SCHWARTZ, Lawrence H et al.Blood. 2011, Vol 117, Num 20, pp 5314-5320, issn 0006-4971, 7 p.Article

Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma: Results From a Multicenter StudyKAHL, Brad S; BARTLETT, Nancy L; CHESON, Bruce D et al.Cancer. 2010, Vol 116, Num 1, pp 106-114, issn 0008-543X, 9 p.Article

Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin LymphomaADVANI, Ranjana H; HORNING, Sandra J; HOPPE, Richard T et al.Journal of clinical oncology. 2014, Vol 32, Num 9, pp 912-918, issn 0732-183X, 7 p.Article

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II StudyPRO, Barbara; ADVANI, Ranjana; YIN YANG et al.Journal of clinical oncology. 2012, Vol 30, Num 18, pp 2190-2196, issn 0732-183X, 7 p.Article

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphomaHORWITZ, Steven M; KIM, Youn H; KOUTSOUKOS, Tony et al.Blood. 2012, Vol 119, Num 18, pp 4115-4122, issn 0006-4971, 8 p.Article

Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell LymphomaCARSON, Kenneth R; BARTLETT, Nancy L; MCDONALD, Jay R et al.Journal of clinical oncology. 2012, Vol 30, Num 26, pp 3217-3222, issn 0732-183X, 6 p.Article

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaFEHNIGER, Todd A; LARSON, Sarah; KEPPEL, Catherine R et al.Blood. 2011, Vol 118, Num 19, pp 5119-5125, issn 0006-4971, 7 p.Article

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasYOUNES, Anas; BARTLETT, Nancy L; LEONARD, John P et al.The New England journal of medicine. 2010, Vol 363, Num 19, pp 1812-1821, issn 0028-4793, 10 p.Article